Kallikrein-related peptidase 6 (KLK6) is a trypsin-like serine protease upregulated at sites of central nervous system (CNS) injury, including de novo expression by reactive astrocytes, yet its physiological actions are largely undefi ned. Taken with recent evidence that KLK6 activates G-protein-coupled protease-activated receptors (PARs), we hypothesized that injuryinduced elevations in KLK6 contribute to the development of astrogliosis and that this occurs in a PAR-dependent fashion. Using primary murine astrocytes and the Neu7 astrocyte cell line, we show that KLK6 causes astrocytes to transform from an epitheliod to a stellate morphology and to secrete interleukin 6 (IL-6). By contrast, KLK6 reduced expression of glial fi brillary acidic protein (GFAP). The stellation-promoting activities of KLK6 were shown to be dependent on activation of the thrombin receptor, PAR1, as a PAR1-specifi c inhibitor, SCH79797, blocked KLK6-induced morphological changes. The ability of KLK6 to promote astrocyte stellation was also shown to be linked to activation of protein kinase C (PKC). These studies indicate that KLK6 is positioned to serve as a molecular trigger of select physiological processes involved in the development of astrogliosis and that this is likely to occur at least in part by activation of the G-protein-coupled receptor, PAR1.
Introduction
Kallikrein 6 (KLK6), also referred to as kallikrein-related peptidase 6, is a member of a family of 15 serine proteases aligned in tandem on human chromosome 19q13.3-4 (Borgono and Diamandis , 2004 ) . Of all kallikreins, KLK6 is the most abundant in the adult central nervous system (CNS) . Within the CNS, KLK6 is expressed at the highest levels in the brainstem and spinal cord where expression is primarily associated with neurons and oligodendrocytes with a relative paucity of expression by astrocytes (Scarisbrick et al. , 2000 (Scarisbrick et al. , , 2001 . In cases of CNS injury however, there is an overall elevation in KLK6 levels within the lesion microenvironment, including an induction of expression by reactive astrocytes . Given the important role that astrocytes play in the response of the CNS to injury and its ability to undergo repair (Bush et al. , 1999 ; Faulkner et al. , 2004 ; Ishida et al. , 2006 ; Fitch and Silver , 2008 ; Li et al. , 2008 ; Rolls et al. , 2009 ; Sofroniew , 2009 ) , we have in this study examined the potential activity of KLK6 in promoting astrogliosis.
Despite the abundance of KLK6 in both the normal and pathologic CNS (Scarisbrick et al. , 1997 (Scarisbrick et al. , , 2000 Terayama et al. , 2004 ; Uchida et al. , 2004 ) , very little is currently known regarding its physiologic and pathophysio logic roles. KLK6 has been shown to degrade extra cellular matrix proteins, including laminin, fi bronectin and heat-denatured collagen, as well as myelin proteins such as myelin basic protein and myelin oligodendrocyte glyco protein Blaber et al. , 2002 ; Scarisbrick et al. , 2002 ) . In addition to degradative actions, we recently demonstrated that KLK6 cleaves thereby activating select members of a family of G-protein-linked receptors referred to as protease-activated receptors (PARs) (Angelo et al. , 2006 ; Oikonomopoulou et al. , 2006a , b ; Vandell et al. , 2008 ) , positioning it to serve as an endogenous signaling molecule in the CNS. There are four known PARs, with PAR1, 2 and 4 activated by proteolytic cleavage of their N-terminus revealing a cryptic tethered ligand that binds intramolecularly to initiate intracellular signaling. PAR3 is also similarly cleaved by proteolysis but it remains controversial the extent to which it signals independently (Ostrowska and Reiser, 2008 ; Seminario -Vidal et al., 2009 ), or rather acts as a regulator of thrombin signaling by serving as a co-factor for PAR4 (Nakanishi -Matsui et al., 2000 ) or by heterodimerizing with PAR1 (McLaughlin et al. , 2007 ) . In a recent study we showed that KLK6 activates PAR1 in neurons and PAR1 and PAR2 in astrocytes to elicit intracellular Ca 2 + fl ux and regulation of the mitogen-activated protein kinase (MAPK) signaling pathway (Vandell et al. , 2008 ) .
PARs have been widely implicated in disease, including CNS pathology (Adams et al. , 2011 ) . PAR1 is commonly referred to as the thrombin receptor and is of particular interest with regard to CNS function and disease because it is not only the most abundant PAR in the CNS (Junge et al. , 2004 ; Vandell et al. , 2008 ) , but has also been implicated in ischemia-related pathogenesis (Striggow et al. , 2001 ), in traumatic spinal cord injury , and in HIV-induced encephalitis (Boven et al. , 2003 ) . At sites of CNS pathology, PAR1 has been linked to direct neural injury (Turgeon et al. , 1998 ; Festoff et al. , 2000 ; Striggow et al. , 2000 ) , in N-methyl-D -aspartate receptor potentiation Hamill et al. , 2009 ; Han et al. , 2011 ) , and in astrogliosis (Wang et al. , 2002 (Wang et al. , , 2007 Boven et al. , 2003 ; Sorensen et al. , 2003 ; Nicole et al. , 2005 ) . Given the upregulation of KLK6 with CNS injury, including de novo expression in reactive astrocytes (Scarisbrick et al. , 2000 , in this study we tested the hypothesis that KLK6 participates in astrogliosis by activation of PAR1. To address this hypothesis we have examined the effects of KLK6 on hallmarks of reactive astrogliosis in vitro , including astrocyte stellation, proliferation, expression of glial fi brillary acidic protein (GFAP) and production of the cytokine interleukin 6 (IL-6).
Results presented indicate that KLK6 is elevated in astrocytes at sites of pathology in the human brain and spinal cord and that KLK6 regulates select aspects of reactive astrogliosis in vitro in a PAR1-dependent fashion. Taken together, these fi ndings support the hypothesis that KLK6 can serve as an endogenous regulator of astrocyte physiology and that elevations in KLK6 at sites of CNS pathology are positioned to participate in events which drive reactive astrogliosis in a graded fashion.
Results

KLK6 is prominent in hypertrophic astrocytes in a variety of human pathological conditions
Cellular hypertrophy is one of the hallmarks of reactive astrogliosis and is a common characteristic of acute and chronic CNS lesions including those seen in spinal cord injury, multiple sclerosis, Alzheimer ' s disease, hydrocephalus, and glioma (Holley et al. , 2003 ; Morcos et al. , 2003 ; Rodriguez et al. , 2009 ) . KLK6 is dense in hypertrophic astrocytes in a variety of human pathological conditions (Figure 1 ). In the uninjured CNS, KLK6-immunoreactivity is predominantly expressed by oligodendroglia ( Figure 1A ) (Scarisbrick et al. , 2000 . Hypertrophic astrocytes in cases of neuropathology are readily recognized by their large size (Morcos et al. , 2003 ) and these were densely KLK6-immunoreactive in spinal cord injury ( Figure 1C ) and multiple sclerosis ( Figure 1E ) cases examined. In glioblastoma multiforme, KLK6-immunoreactivity was also prominent in astrocytes and readily evident in those with a gemistocytic morphology as seen in Figure 1G . The prominence of KLK6 in reactive astrocytes across a range of CNS disorders, but not in astrocytes of uninjured brain (Scarisbrick et al. , 2000 (Scarisbrick et al. , , 2001 , underscores the need to determine whether KLK6 may be a signifi cant contributor to the process of astrogliosis.
KLK6 promotes astrocyte stellation
The potential impact of KLK6 on murine astrocyte morphology was determined by analysis of the arrangement of cytoskeletal actin in response to treatment with recombinant enzyme. Since serum can cause high basal levels of astrocyte stellation, and contains both proteases and protease inhibitors, all experiments were performed using defi ned serumfree media. Under these conditions more than 90 % of all primary astrocytes were non-stellate, that is, they did not have two or more processes at least one cell body in length (11.6 ± 5.8 % stellate, Figure 2 ) . Treatment of primary astrocytes with 300 n m (10 μ g/ml) recombinant KLK6 resulted in a sevenfold increase in stellation over a period of 24 h (74.1 ± 5.1 % stellate, Figure 2B ). By contrast at parallel concentrations, another member of the kallikrein gene family, KLK1 , which was expressed and activated under conditions identical to KLK6 (Laxmikanthan et al. , 2005 ) , did not alter astrocyte shape ( Figure 2C ). Subsequent experiments to determine the temporal features of the KLK6-stellation response indicated that signifi cant changes in stellation could already be observed by 4 h after KLK6 application ( Figure 2H , p < 0.05, SNK). Since we recently demonstrated that KLK6 can activate astrocyte PAR1 and PAR2 (Vandell et al. , 2008 ) , and activation of these receptors is known to promote a non-stellate morphology (Wang et al. , 2002 (Wang et al. , , 2007 Sorensen et al. , 2003 ; Nicole et al. , 2005 ; Park et al. , 2006 ) , we examined the effects of peptides that specifi cally activate each receptor (PAR1-and PAR2-APs). In agreement with prior studies, when treated with PAR1-(40 μ m ) or PAR2-APs (200 μ m ), primary astrocytes maintained an epitheliod, non-stellate appearance. The effects of KLK6 were also compared to effects of lipopolysaccharide (LPS) which other studies indicate promotes astrocyte activation (Brahmachari et al. , 2006 ) . Treatment of primary astrocytes with LPS (25 μ g/ml) resulted in robust astrocyte stellation (73.2 ± 1.9 % stellate, Figure 2F ) paralleling the response observed with KLK6 treatment. KLK6-induced stellation in primary astrocytes was blocked by the pan-serine protease inhibitor aprotinin ( Figure 2J ).
While much remains to be learned regarding what would be considered physiological levels of KLK6 in the brain and the changes that occur with injury and disease, the level of KLK6 in human cerebrospinal fl uid has been shown to range from 0.5 to over 30 μ g/ml (Zarghooni et al. , 2002 ; Borgono and Diamandis , 2004 ; Shaw and Diamandis , 2007 ) . We therefore examined the effects of a range of KLK6 concentrations to determine the minimal dose suffi cient to promote astrocyte stellation (Figure 2 ). There was a dose-dependent increase in KLK6-triggered stellation at both 30 n m (1 μ g/ml, 38.1 ± 2.1 % stellate) and at 300 n m (10 μ g/ml, 64.8 ± 5.4 % stellate), each promoting a signifi cant increase relative to controls (11.6 ± 5.8 % stellate), while treatment with 3 n m (0.1 μ g/ml) trended towards an increase but did not reach the level of statistical signifi cance at the 24 h time point ( p < 0.05). The stellation promoting effects of KLK6 in vitro therefore occur over a range of concentrations that would be considered phy siological relative to normal human CSF and which are likely to be encompassed by the elevated levels known to occur in cases of CNS pathology (Scarisbrick et al. , 1997 Uchida et al. , 2004 ) .
The ability of KLK6 to promote astrocyte stellation was further evaluated using the Neu7 murine astrocyte cell line (Fok -Seang et al., 1995 ) that we have utilized in prior studies to dissect KLK6-receptor-mediated signaling cascades (Vandell et al. , 2008 ) . Notably, Neu7 astrocytes have a high basal level of stellation under the defi ned media conditions used herein, permitting further comparisons between the stellation promoting/reversing effects of KLK6 relative to PAR-APs without the introduction of serum (Figure 3 A -G). Neu7 astrocytes grown on charged cover glass were treated with concentrations of KLK6, KLK1 or PAR-APs identical to those used in experiments involving primary astrocytes. Under resting conditions, Neu7 astrocytes exhibited a high basal level of stellation (74.5 ± 2.1 % stellate). PAR1-and PAR2-APs caused a signifi cant reversal of astrocyte stellation leaving only 26.7 ± 4 % and 44.7 ± 4.1 % of cells stellate, respectively ( p < 0.001). PAR-inactive ' scrambled ' control peptides had no effect on stellation (not shown). These observations parallel those of prior studies which have demonstrated the ability of PAR1-and PAR2-APs to reverse astrocyte stellation in cultures with high basal stellation levels (Debeir et al. , 1997 ; Pindon et al. , 1998 ; Nicole et al. , 2005 ; Park et al. , 2006 ) . Since we have shown KLK6 activates both PAR1 and PAR2 in Neu7 astrocytes, the expected result with KLK6 treatment would be a parallel reversal of stellation. Instead of reversing astrocyte stellation, however, and mirroring the results seen in primary astrocytes, KLK6 induced a signifi cant increase in the number of stellate astrocytes (85.2 ± 1.2 % stellate, p = 0.002). In addition to increasing the number of stellate cells present, KLK6 also increased astrocyte process length from an average of 29.1 ± 1.3 μ m to 36.6 ± 0.8 μ m ( p < 0.001, Figure 3H ). As was the case for primary astrocytes, identical treatment with recombinant KLK1 did not alter the morphology of Neu7 astrocytes (79.1 ± 1.7 % stellate).
Given the opposing effects of KLK6 and PAR1-AP on stellation of Neu7 astrocytes, we examined the effect of concomitant treatment ( Figure 3I ). In this series of experiments, Neu7 astrocytes treated with vehicle alone were 66.6 ± 4.9 % stellate, while those treated with PAR1-AP showed the expected reversal of stellation (16.9 ± 4.6 % stellate), and those treated with KLK6 showed enhanced stellation (78.2 ± 2 % stellate). When Neu7 astrocytes were treated simultaneously with both PAR1-AP and KLK6, stellation reversal was still observed, but the magnitude was significantly reduced (35.8 ± 2.9 % stellate, p = 0.005). We note that the cleavage specifi city of KLK6 is hydrolysis C-terminal to arginine and therefore we would not expect KLK6 to cleave and inactivate the PAR1-AP (TFLLR-amide) directly, although we did not directly test this possibility. The ability of KLK6 to oppose PAR1-induced stellation reversal was blocked by the pan-serine protease inhibitor 4-amidinophenylmethanesulfonyl fl uoride hydrochloride (APMSF, p = 0.004, Figure 3 ). In normal-appearing spinal cord white matter (A, B), KLK6 is prominent in oligodendrocytes which bear round nuclei and a thin rim of cytoplasm (arrows, A), while astrocytes are not prominently stained (Scarisbrick et al. , 2000 (Scarisbrick et al. , , 2001 ) (B, shows adjacent LFB/PAS). In cases of traumatic spinal cord injury (C) and in multiple sclerosis lesions (E), KLK6 immunoreactivity is dense in hypertrophic astrocytes (D and F show Luxol fast blue/periodic acid-Schiff stains in near adjacent sections demonstrating myelin loss; small arrows A and C indicate KLK6-immunoreactive oligodendrocytes, large arrows C and E indicate hypertrophic astrocytes). KLK6 is also dense in astrocytes with a gemistocytic morphology seen in glioblastoma multiforme tumor samples (G, large arrows). Scale bar = 50 μ m in panels A -G.
PAR1 activation is necessary for KLK6-induced astrocyte stellation
To evaluate the involvement of PAR1 in mediating KLK6-induced astrocyte stellation, primary or Neu7 astrocytes were treated with either vehicle alone or the PAR1 antagonist SCH79797 (35 n m ) for 30 min, followed by application of KLK6 at 30 or 300 n m (1 or 10 μ g/ml) for 24 h (Figure 4 A,B). Pre-treatment with the PAR1 antagonist alone did not alter astrocyte stellation under control conditions in primary or 
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Process length (μm) signifi cantly increased stellation above baseline, while treatment with PAR1-, PAR2-, or combined PAR1-and PAR2-APs, caused signifi cant stellation reversal. KLK1 did not signifi cantly alter stellation. (H) KLK6-triggered stellation was associated with a signifi cant increase in astrocyte process length. (I) Less PAR1-AP-mediated stellation reversal was observed when cells were concomitantly treated with KLK6. The ability of KLK6 to decrease PAR1-mediated stellation reversal was blocked by the serine protease inhibitor APMSF. * p < 0.05, SNK. Scale bar = 100 μ m in panels A -F.
Neu7 astrocytes. The PAR1 inhibitor did however block the ability of 300 n m KLK6 to induce stellation in Neu7 astrocytes (63.5 ± 1.7 % compared to 76.4 ± 2.2 % for cells treated with KLK6 alone, p < 0.001) and in primary astrocytes treated with 30 n m of KLK6 (5.2 ± 1.7 compared to 22.8 ± 3.5 for cells treated with KLK6 alone, p < 0.001). At higher KLK6 concentrations (300 n m ), which induced very high levels of stellation above baseline, reductions in primary astrocyte stellation seen with the PAR1 inhibitor did not reach the level of statistical signifi cance.
KLK6-induced astrocyte stellation is mediated by protein kinase C
In order to begin to address the intracellular signaling pathways that mediate KLK6-induced stellation, primary or Neu7 astrocytes were pre-treated with vehicle alone or the protein kinase C (PKC) inhibitor Go6983 (60 n m ) for 30 min prior to application of KLK6 (300 nm) and cells incubated for an additional 24 h ( Figure 5 ). The PKC inhibitor blocked KLK6-induced stellation in both primary and Neu7 astrocytes. In primary astrocytes, KLK6-treated cells were 53.7 ± 4.0 % stellate while this was reduced to 12.0 ± 3.7 % when PKC was blocked. In Neu7 astrocytes treatment with KLK6 resulted in 75.4 ± 2.8 % stellate and pre-treatment with the PKC inhibitor reduced KLK6-mediated stellation to 56.7 ± 3.8 % , ( p < 0.05) ( Figure 5B ).
Effects of KLK6 on IL-6 secretion, GFAP expression and astrocyte proliferation
The participation of KLK6 in astrogliosis was further evaluated by determining its ability to impact three additional hallmarks of reactive astrocytes; IL-6 secretion (Hariri et al. , 1994 ) , GFAP expression (Eng et al. , 2000 ) , and proliferation (Nicole et al. , 2005 ; Wang et al. , 2007 ) . KLK6 treatment (300 n m , 24 h) elicited a two-fold increase in IL-6 secretion from primary astrocytes (166.9 ± 5.1 pg/ml KLK6-treated compared to 79.8 ± 2.1 pg/ml in the case of controls) (Figure 6 A). By contrast, GFAP RNA expression was signifi cantly decreased in the same cultures ( Figure 6B ). Quantifi cation of the mean number of 4 ′ ,6-diamidino-2-phenylindole (DAPI)-stained nuclei across experiments (Figure 2 ) indicated KLK6 does not cause a signifi cant increase in astrocyte number ( Figure 6C ).
Discussion
Despite the fact that reactive astrogliosis is a ubiquitous component of CNS injury and disease, and essential to the wound-healing process, the extracellular factors and intracellular mechanisms mediating this response are poorly understood. We have identifi ed KLK6 as a novel serine protease with abundant expression in adult CNS and which is induced in astrocytes with neurological injury (Scarisbrick et al. , 1997 (Scarisbrick et al. , , 2000 (Scarisbrick et al. , , 2001 ). Given our recent fi ndings demonstrating the ability of KLK6 to activate astrocyte PARs (Vandell et al. , 2008 ) , we hypothesize that elevations in KLK6 available from astrocyte and non-astrocyte sources at sites of CNS pathology promote astrogliosis. Studies herein demonstrate that KLK6 is capable of mediating discrete aspects of astrogliosis, including induction of a stellate morphology and IL-6 production. The ability of KLK6 to promote astrocyte stellation was further shown to be dependent, at least in part, on activation of PAR1 and the PKC intracellular signaling pathway. These studies therefore identify a novel molecular signaling pathway mediating astrogliosis in vitro that warrants further study as a target to modulate the development of astroglial scar tissue in cases of neurological injury and disease.
KLK6 promotes astrocyte stellation
Astrocytes treated with KLK6 rapidly transform from an epitheliod polygonal shape to a stellate morphology. Astrocytes are known to be morphologically plastic and their shape plays a critical role in their functional properties (Eng et al. , 2000 ; Liu et al. , 2000 ; Messing and Brenner 2003 ; Sofroniew 2009 ). The most exaggerated KLK6-induced stellation response was seen in primary astrocytes which exhibit a low resting level of stellation under defi ned culture conditions. Notably, KLK6 also promoted stellation of the Neu7 astrocyte cell line which had an overall higher basal level of stellation at rest. By contrast to the effects of KLK6, activation of either the thrombin receptor PAR1, or PAR2, 
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Stellate ( or a combination of these receptors using synthetic peptide mimics (PAR-APs) promoted a reversal of astrocyte stellation when resting stellation levels were high, as seen in the Neu7 astrocyte cell line. These results parallel prior studies which show that thrombin, trypsin or PAR1-AP all promote reversal of astrocyte stellation (Cavanaugh et al. , 1990 ; Debeir et al. , 1997 ; Pindon et al. , 1998 ; Park et al. , 2006 ) and point to the unique capacity of KLK6 to drive astrocytes toward a stellate morphology. Interestingly, thrombin is also elevated at sites of CNS injury, largely by extravasation from blood . Since thrombin and PAR1 activation promote a reversal of astrocyte stellation, and we show herein that KLK6 can partially oppose these effects, it is possible that elevations in KLK6 in CNS lesions serves in part to counterbalance the PAR1-mediated effects of thrombin, and that this continuum of proteolytic activity plays a unique role in regulating astroglial biology, including cellular morphology. To begin to understand the functional signifi cance of stellation to the process of astrogliosis, we compared the effects of KLK6 to those of LPS, a pro-infl ammatory component of the cell wall of Gram-negative bacteria, which is known to promote astrocyte activation in vitro (Brahmachari et al. , 2006 ) and in vivo (Guerra et al. , 2011 ) . Notably, like KLK6, LPS promoted robust stellation of primary astrocytes. Taken together these data support the view that stellation is an important component of the physiological processes that take place during the astrocyte activation cascade and that KLK6 is a newly identifi ed participant. Since our prior studies demonstrate that KLK6 is expressed de novo in reactive astrocytes , and current studies demonstrate expression in hypertrophic astrocytes in a range of human CNS pathologies, including spinal cord injury, multiple sclerosis and glioblastoma multiforme, we hypothesize that astrocyte-KLK6 acts in an autocrine or paracrine fashion to regulate specifi c aspects of the astrogliosis cascade, including astrocyte stellation. While the functional signifi cance of stellation in vivo is not clear, one can envision that this morphological change may not only affect permeability of the blood brain barrier, but also play an important role in wound healing and the eventual development of glial scar tissue, each a common feature across CNS pathologies.
PAR1 activation is necessary for KLK6-induced astrocyte stellation
While KLK6 promoted astrocyte stellation and activation of PAR1 promoted stellation reversal, it is interesting that blocking PAR1 activation alone, by pre-incubation of cells with the PAR1-specifi c inhibitor SCH79797 (Ma et Vandell et al. , 2008 ) , signifi cantly reduced KLK6-astrocyte-stellation promoting effects. These results support the concept of biased agonism at PAR1, whereby activation of the same receptor by different agonists has divergent physiological effects. For example, there are several prior reports that activation of PAR1 can result in divergent phenotypes depending on the agonist involved. While both thrombin and activated protein C activate PAR1 on endothelial cells, thrombin induces changes in endothelial cells which promote breakdown of the blood-brain barrier, while activated protein C promotes blood-brain barrier integrity (Feistritzer and Riewald , 2005 ) . Notably, activated protein C retains its protective effects even in the presence of high concentrations of thrombin (Schuepbach et al. , 2008 ) , mirroring the ability of KLK6 to oppose PAR1-AP stellation reversal. Thrombin and activated protein C signaling also produce markedly different changes in gene expression in cytokine-stimulated cells (Riewald and Ruf , 2005 ) . Other studies indicate that divergent physiologic effects depending on the specifi c PAR1 agonist may refl ect differences in receptor traffi cking, compartmentalization and/or transactivation events. Following activation of PAR1 by thrombin for example, PAR1 is rapidly internalized, while after activation by activated protein C, PAR1 remains on the cell surface (Schuepbach et al. , 2008 ) . Recent studies also suggest that compartmentalization of PAR1 in caveolae is critical for activated protein C-specifi c endothelial protective effects (Russo et al. , 2009 ) . While results in the present study demonstrate that PAR1 is a necessary component of the signaling pathway that results in KLK6-induced stellation, these results do not rule out the involvement of other receptors, including PAR2 which we have shown KLK6 activates in astrocytes (Vandell et al. , 2008 ) , and in other cell types (Oikonomopoulou et al. , 2006a ; Oikonomopoulou et al. , 2006b ). Interestingly, depending on the agonist, activation of PAR1 has also been associated with transactivation of the epidermal growth factor receptor (Prenzel et al. , 1999 ; Darmoul et al. , 2004 ; Arora et al. , 2008 ) and potentiation of N-methyl-D -aspartate receptor responses Hamill et al. , 2009 ; Han et al. , 2011 ) . Any differences in receptor localization, traffi cking or transactivation between KLK6 and PAR1-AP-mediated activation of PAR1, and how this may affect intracellular signaling and astrocyte stellation will require further study. The results herein do support the concept that KLK6 signals at least in part through PAR1 to mediate astrocyte stellation and therefore PAR1 may serve as a target to modulate KLK6-induced changes in astrogliosis in cases of CNS injury.
PKC signaling is necessary for KLK6-induced astrocyte stellation
The ability of KLK6 to promote astrocyte stellation depends on signaling through PKC since the stellation promoting effects of KLK6 were blocked by a PKC small molecule inhibitor. Prior studies have shown that activation of the PKC signaling cascade is essential to the regulation of astrocyte stellation with the effects observed dependent on the duration of activation. For example, a short 90-min exposure of astrocytes to the PKC activator PMA induced stellation reversal (Pindon et al. , 1998 ; Park et al. , 2006 ) , while longer treatment periods, on the order of several hours, promoted stellation (Abe and Saito , 2000 ) . This is of particular interest with regard to the concept of biased agonism because it is possible that KLK6 and PAR1-AP engagement of the thrombin receptor differentially activate downstream signaling pathways such as PKC resulting in differential phenotypic effects, namely stellation or reversal of stellation. The PKC family contains at least 12 different isoforms and PAR1 has been shown to activate the α , β , δ and ε isoforms across a range of cell types (Pindon et al. , 1998 ; Fang et al. , 2004 Fang et al. , , 2008 Chiu et al. , 2008 ) . Of these, only the β -1 isoform has been linked to PAR1-mediated stellation reversal (Pindon et al. , 1998 ) . No specifi c PKC isoform has yet been linked to the promotion of astrocyte stellation, but the PKC inhibitor Go6983, shown to block KLK6-induced stellation herein, is known to inhibit the α , β , γ , δ , and ζ isoforms, suggesting that one or more of these may be involved.
KLK6 stimulates IL-6 secretion but suppresses GFAP mRNA expression
In addition to promoting robust astrocyte stellation, treatment of astrocyte cultures with KLK6 promoted secretion of IL-6. IL-6 is a cytokine known to be upregulated in reactive astrocytes and to be an important component of astroglial pathophysiology (Hariri et al. , 1994 ) . Interestingly, blockade of IL-6 has been shown to reduce astrogliosis, infl ammation and connective tissue scarring and to improve behavioral outcomes in murine models of traumatic spinal cord injury (Okada et al. , 2004 ) . IL-6 is also known to play an important role in the development and malignant progression of astrocytomas (Weissenberger et al. , 2004 ) . Therefore, elevations in KLK6 at sites of CNS pathology Blaber et al. , 2004 ; Terayama et al. , 2004 ; Uchida et al. , 2004 ) , including de novo expression by astrocytes , are in a position to drive IL-6-mediated effects in an autocrine or paracrine fashion. Targeting KLK6 therefore may represent a novel strategy to regulate IL-6 and the pleiotropic actions of this cytokine in a range of CNS pathological conditions. While KLK6 promoted robust astrocyte stellation, and IL-6 secretion, it signifi cantly reduced the expression of another cardinal feature of reactive astrogliosis, namely, expression of GFAP. GFAP is the major intermediate fi lament protein present at low levels in resting astrocytes and among those proteins known to be up regulated in the injured CNS (Sofroniew 2009 ) . Interestingly, prior studies examining the effects of PAR1-AP on GFAP levels also point to suppressive effects at a protein level (Nicole et al. , 2005 ) .
Underscoring the likely unique roles played by KLK6 in the process of reactive astrogliosis, KLK6 was not seen to promote astrocyte proliferation. By contrast, trypsin, thrombin and PAR1-AP have each been identifi ed as potent astrocyte mitogens (Perraud et al. , 1987 ; Wang et al. , 2002 ; Nicole et al. , 2005 ) , and proliferation is considered another hallmark of astrogliosis. Taken together, the selective effects of KLK6 in mediating astrocyte stellation and IL-6 secretion, while suppressing GFAP production, support the concept that KLK6 plays unique physiological roles in the spectrum of events that characterize astrogliosis. Further studies will be necessary to determine whether the astrocyte-specifi c effects triggered by KLK6 can be modulated to facilitate repair in cases of neurological injury or disease.
Materials and methods
KLK6 in human CNS lesions
All human materials studied were formalin-fi xed paraffi n-embedded archival material obtained at autopsy. All cases of chronic spinal cord injury examined were defi ned as greater than one month post-injury (n = 10, mean time post injury 1844 ± 846 days), and were confi rmed as traumatic contusion or transection injury cases by chart review. The cause of injury refl ected that in the general population with 68 % a result of motor vehicle accident, 21 % falls and 11 % sports-related injury. Chronic active multiple sclerosis lesions studied (n = 5) were clinically and pathologically confi rmed cases (Poser et al. , 1983 ) . Glioblastoma multiforme cases examined (n = 32) were arrayed as tumor core samples in triplicate on glass microscope slides. All glioblastoma multiforme cases were histologically proven as World Health Organization (WHO) Grade IV. Deparaffi nized sections (5 μ m) were stained for KLK6 using a KLK6-specifi c monoclonal antibody (MSP-3-3, 20 μ g/ml) (Scarisbrick et al. , 2001 ; Scarisbrick et al. , 2002 ) and standard immunoperoxidase techniques. Prior to staining, endogenous peroxidase activity was blocked by 0.3 % hydrogen peroxide, sections treated with citrate buffer (pH 7.0, BioGenex, San Ramon, CA, USA) and non-specifi c binding blocked with 20 % normal goat serum. Following incubation with primary and biotinylated species appropriate secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA), KLK6 immunoreactivity was visualized with 3 ′ ,3 ′ -diaminobenzadine tetrahydrochloride as the substrate. Tissue sections processed in the absence of primary antibody served as a control for potential non-specifi c binding of secondary antibodies. Immunostained sections were counterstained with Gill ' s Hematoxylin and adjacent sections examined for pathology in the case of multiple sclerosis and spinal cord injury lesions using Luxol fast blue/periodic acid-Schiff (LFB/PAS). The use of human materials in this study was approved by the Mayo Clinic Institutional Review Board and all clinical follow-up was obtained by review of medical records.
Cell culture
Primary astrocytes were isolated from postnatal day 1 C57/BL6J mice (Jackson Laboratories, Bar Harbor, ME, USA) essentially as described previously (Stieg et al. , 1980 ) . Following isolation, astrocytes were expanded in Dulbecco ' s Modifi ed Eagle Medium with 10 % fetal calf serum, 0.45 % glucose, 2 m m Glutamax, 1 m m sodium pyruvate, and 50 U/ml penicillin-streptomycin for 10 days on poly-D -lysine coated cell culture plastic (Sigma, St. Louis, MO, USA). Prior to subculturing astrocytes in defi ned serum-free media, oligodendroglia were removed from the cultures by overnight shaking at 200 rpm. Cultures of primary astrocytes were > 95 % pure based on immunoreactivity for GFAP. The Neu7 astrocyte cell line was generated by retroviral immortalization of murine cortical astrocytes (Fok -Seang et al., 1995 ) and was kindly provided by Dr. Herb Geller (National Institutes of Health, Bethesda, MD, USA). Neu7 astrocytes express GFAP (Heck et al. , 2003 ) and mirror properties of an astroglial scar in that they produce an extracellular matrix inhibitory to neurite outgrowth (Fok -Seang et al., 1995 ) . All experiments were performed on cells cultured in defi ned serum-free media which consisted of Neurobasal A media supplemented with 2 % B27, 1 % N2 (Invitrogen, Carlsbad, CA, USA), 50 U/ml penicillin-streptomycin, 0.45 % glucose, 2 m m Glutamax, 1 m m sodium pyruvate and 50 μ m β -mercaptoethanol. In all cases cells were grown on surfaces coated with 10 μ g/ml poly-D -lysine. All cells were maintained at 37 ° C in 95 % air and 5 % CO 2 . All animal studies were performed in adherence to NIH Guidelines for animal care and safety and were approved by the Mayo Clinic Institutional Animal Care and Use Committee.
Recombinant KLK1 and KLK6 protein production
Recombinant mature KLK1 and KLK6 protein was produced from insect cell heterologous expression as previously described Blaber et al. , 2002 ; Laxmikanthan et al. , 2005 ) . Briefl y, an amino terminal 6 × -His tag and enterokinase (Asp 4 -Lys) prosequence was substituted for the KLK1 and KLK6 pro-sequence to enable effi cient purifi cation and subsequent controlled activation by enterokinase (EK). EK activation was performed under acidic pH conditions to limit any subsequent KLK6 autolytic inactivation (in contrast, KLK1 does not undergo internal autolysis). EK, mature KLK and released pro-peptide have substantially different molecular masses and were effectively and rapidly separated by size exclusion chromatography. The fi nal purifi ed mature KLK1 and KLK6 protein were characterized by N-teminal sequence analysis to quantify the extent of activation (and potential autolysis), and by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS PAGE; combined with Coomassie Brilliant Blue staining and scanning densitometry) to quantify overall purity as well as extent of any autolysis. Mature purifi ed KLK1 and KLK6 N-terminal sequencing showed the correct mature N-terminus, in both cases, with no evidence of the 6 × -His uncut pro-peptide. Scanning densitometry of the SDS PAGE showed an overall purity of > 95 % for both KLK1 and KLK6 proteins. MALDI-TOFF mass spectrometry analysis showed a principle mass of 28 780 Da for purifi ed KLK1 and 25 866 Da for purifi ed KLK6, indicating the presence of 13 N-acetylglucosamine moieties at the single site of glycosylation at residue Asn95 in KLK1 and six N-acetylglucosamine moieties at the single site of glycosylation at residue Asn132 in KLK6. Mass spectrometry showed minor heterogeneous glycosylation for both proteins and involving 1 -6 additional 180 Da hexose units (resulting in increased mass heterogeneity of 0.7 -4.2 % ); thus, 28.8 kDa and 25.9 kDa were utilized as the molecular mass of the purifi ed KLK1 and KLK6 proteins, respectively; and an extinction coeffi cient of E 280 1 cm (1 % ) = 18.0 AU and 12.8 AU, respectively, were utilized for routine determination of protein concentration. Purifi ed KLK1 and KLK6 proteins were subjected to spectrofl uorometric active site titration using 4-methylumbelliferyl 4-guanidinobenzoate (MUGB). The ester complex with these kallikrein-related peptidases is not as stable as with trypsin, however burst titration can be effectively extrapolated to the zero time point to determine active site concentration. This analysis indicated approximately 90 % and 85 % active protein for KLK1 and KLK6 proteins, respectively, based upon their individual extinction coeffi cients, and therefore in good agreement with the overall purity and integrity of the mature forms as determined by the N-terminal sequencing and SDS PAGE scanning densitometry. Thus, active site titration indicates essentially all the mature KLK1 and KLK6 protein is correctly folded and active, in good agreement with the X-ray structure determination of both proteins produced and purifi ed by these same methods Laxmikanthan et al. , 2005 ) .
Astrocyte stellation assay
The ability of KLK6 to alter astrocyte stellation and the possible involvement of PAR1 in this process was examined using a combination of recombinant kallikrein, PAR-activating peptides, and a PAR1 specifi c inhibitor, SCH79797 (Wang et al. , 2006 ; Strande et al. , 2007 ; Grisaru -Granovsky et al., 2009 ) . First, the effects of treating primary astrocytes or the Neu7 astrocyte cell line for 24 h with recombinant KLK1 or KLK6, each at 300 n m (10 μ g/ml), or with PAR1-(TFLLRamide, 40 μ m ) or PAR2-APs (SLIGRL-amide, 200 μ m ) (Peptides International, Louisville, KY, USA) were compared. PAR-APs mimic the tethered ligand of their respective receptors and therefore mediate receptor-specifi c activation. The concentrations of PAR-APs and KLK6 used were those we have demonstrated are suffi cient to evoke Ca 2 + fl ux and MAPK signaling in Neu7 astrocytes (Vandell et al. , 2008 ) . Negative control peptides for PAR1-(RLLFT-amide) and PAR2-(VKGILSamide) were also examined at parallel concentrations. The minimal dose of KLK6 required to promote stellation of primary astrocytes was established by quantifying the effects of 3, 30 or 300 n m (0.1, 1 or 10 μ g/ml) at the 24-h time point. The time course of the stellation response was also determined by examination of cells at 30 or 90 min as well as 4, 8 or 24 h post-KLK6 treatment. To determine whether KLK6-specifi c effects on astrocyte stellation were mediated by its enzymatic properties, stellation experiments were repeated using KLK6 that had been pre-incubated for 30 min with a pan-serine protease inhibitor, either APMSF (50 μ m ) or aprotinin (5 μ m , Sigma). The involvement of PAR1 in KLK6-mediated changes in astrocyte stellation was examined using a PAR1-specifi c inhibitor, SCH79797 (35 n m , Tocris, Minneapolis, MN, USA). SCH79797 is a selective non-peptide antagonist of PAR1 that has demonstrated specifi city in vitro in a wide variety of cell types including, mouse kidney cells (Hocherl et al. , 2011 ) , a mouse motoneuron cell line (Vandell et al. , 2008 ) , rat primary astrocytes (Wang et al. , 2006 ) and gingival fi broblasts (Ohuchi et al. , 2011 ) , as well as human melanoma (Silini et al. , 2011 ) and cytotro phoblast cells (Grisaru -Granovsky et al., 2009 ). The role of PKC signaling was examined using a PKC specifi c inhibitor (Go6983, 60 n m , Tocris). SCH79797 or Go6983 were applied to cells 30 min prior to the application of recombinant KLK6.
To examine astrocyte stellation, astrocytes were plated at a density of 12 500 cells per cm 2 on poly-D -lysine coated cover slips. Following treatment, cells were fi xed in 2 % paraformaldehyde, permeabilized with 0.1 % Triton X-100, stained with 1 U rhodamine-conjugated phalloidin (Invitrogen) to visualize actin. Phalloidin-stained cells were cover-slipped using 4 ′ ,6-diamidino-2-phenylindole (DAPI) containing Vectashield mounting media enabling enumeration of all cells in each case (Vector Laboratories, Burlingame, CA, USA). Five digital images were collected at 20 × magnifi cation per cover slip in predetermined fi elds (at the center and four poles) using an Olympus AX70 microscope equipped with SPOT software (Olympus, Center Valley, PA, USA). Astrocytes were scored as stellate if they possessed two or more processes at least one cell body in length. Astrocyte process length was measured using Interactive Pathology Laboratory software (BD Biosciences, Franklin Lakes, NJ, USA). Cell number was determined by enumeration of the mean number of DAPI-labeled nuclei in each microscopic fi eld. In each case, cells were treated in triplicate and experiments repeated at least twice. At least 300 cells were scored without knowledge of the treatment conditions in each experiment and stellation in treated and untreated conditions compared using unpaired Student's t -tests.
Quantitative polymerase chain reaction and ELISA
In addition to determining the effect of KLK6 on astrocyte stellation, its ability to alter other facets of astrogliosis, namely IL-6 secretion and GFAP expression were also examined. To determine the potential effect of KLK6 on IL-6 secretion and GFAP expression, primary cortical astrocytes were grown in six well plates and treated with either vehicle alone or KLK6 (300 n m ) for 24 h. Cell culture supernatants were collected and snap frozen at -70 ° C for measurement of IL-6 protein. IL-6 secretion was measured in cell culture supernatants using the eBioscience Mouse IL-6 ELISA kit according to the manufacturer ' s instructions (eBioscience, San Diego, CA, USA).
GFAP expression was quantifi ed in RNA isolated using RNA STAT-60 (Tel-Test Inc., Friendswood, TX, USA) from KLK6-treated or untreated cultures. The level of mRNA expression in each case was determined in 0.25 μ g of RNA using Light Cycler RNA Amplifi cation SYBR Green I (Roche, Basel, Switzerland) and an iCycler iQ5 (BioRad, Hercules, CA, USA). GFAP mRNA copy number was normalized to the level of the constitutively expressed gene, glyceraldehyde phosphate 3-dehydrogenase (GAPDH), amplifi ed in the same sample. In each case copy number was determined by parallel amplifi cation of cDNA clones diluted to known copy number as previously described . Forward and reverse primers used for GFAP were 5 ′ -GCA GAT GAA GCC ACC CTG G-3 ′ and 5 ′ -GAG GTC TGG CTT GGC CAC-3 ′ , and for GAPDH were 5 ′ -ACC ACC ATG GAG AAG GC-3 ′ and 5 ′ -GGC ATG GAC TGT GGT CAT GA-3 ′ , respectively.
